U.S. Patents Issued for Akonni Biosystems’ Novel Thermal Cycling Technology

  U.S. Patents Issued for Akonni Biosystems’ Novel Thermal Cycling Technology

   The First Temperature Control Device to Enable Rapid PCR in a Microarray
                               Reaction Chamber

Business Wire

FREDERICK, Md. -- February 7, 2013

Akonni Biosystems, a developer of nucleic acid extraction products that are
2-fold to 5-fold faster than industry gold standards, and low-cost
mid-multiplex platforms for genetic testing, announced today that the United
States Patent and Trademark Office issued two patents for its novel method for
amplifying nucleic acids using polymerase chain reaction (PCR).

U.S. Patent Nos. 8,329,433 and 8,334,117 describe a rapid thermal cycling
approach for PCR applications that is virtually independent of reaction
chamber geometry. The approach exploits the efficient convective heat transfer
mode using a recirculating liquid that expands a flexible film and can perform
45 PCR cycles in 25 minutes. These patents protect Akonni's pioneering
approach to thermal cycling and give companies an alternative to the
conductive heating of Peltier devices commonly used by leading manufacturers
such as Life Technologies (LIFE), Bio-Rad (BIO), Roche (RO) and Cepheid
(CPHD).

“These new flexible film controlled heating elements give Akonni the unique
ability to rapidly amplify nucleic acids and detect disease biomarkers within
a single enclosed reaction chamber on its proprietary plastic-based microarray
consumable,” said Kevin Banks, Ph.D., Vice President of Strategic Development
for Akonni. “The components resulting from these patents are integral to the
development of our next generation of systems for low-cost mid-multiplex
genetic testing in point-of-care settings.”

“These patents expand Akonni's intellectual property position in the field of
mid-multiplex microarray-based technologies for rapidly identifying infectious
pathogens and genetic disease,” said Banks.

About Akonni Biosystems

Akonni develops highly innovative products and technologies designed to
significantly increase productivity in the life science tools/sample
preparation market and to dramatically lower the cost of testing in the
molecular diagnostics (MDx) market. Akonni Biosystems was founded in 2003 and
has more than 48 patents issued or pending. Supported by a series of
government grants and contracts from NIH, CDC, DOE, DOD, NIJ, and NSF, the
company has built on its founding technology by improving capabilities from
sample preparation to final result. Akonni products and near-term pipeline
projects include rapid sample preparation methodologies for nucleic acid
extraction and mid-multiplex panel assays for detecting multi-drug-resistant
tuberculosis (MDR-TB), upper respiratory infections, viral encephalitis, and
healthcare-associated infections (MRSA).

Akonni products are currently for research use only. Not for use in diagnostic
procedures.

For more information, please visit www.akonni.com.

Contact:

For Akonni Biosystems:
Kevin Banks, 301-698-0101 ext. 287
kbanks@akonni.com
or
For Press Inquiries:
GeneCom Group
Annette Summers, 925-519 0608
Annette@genecom.biz
 
Press spacebar to pause and continue. Press esc to stop.